Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.
This combination of email and password didn't match our records. Your account might not be activated. If so, please click on the link we sent you via email. You can also request a password reset or a new activation email using the links below.
: AALB NA, ARGX BB, HYL BB
Hyloris announced an exclusive license and supply agreement with Avenacy for tranexamic acid RTU in the US. The deal is set up as a profit sharing agreement with commercialisation expected to start in 2025. We reiterate our € 5 TP and Hold rating.
: COFB BB
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.